Neoadjuvant therapy was defined as a cytoreductive therapy administered prior to a definitive locoregional treatment--surgical resection. While surgical resection can be curative in patients diagnosed with localized early-stage non-small cell lung cancer, patients with nodal (N1, N2) disease are generally not candidates for exclusive surgery. Inductive therapy can improve the microscopic metastatic disease, eradicate the primary tumor and thereby improve survival.

Antineoplastic Combined Chemotherapy Protocols↗

PubMedDate not supplied

HLA antigens associated with sarcoidosis.

In a series of 123 sarcoidosis patients (inhabitants of Moravia), frequencies of 15 HLA-A, 31 HLA-B, and 7 HLA-C antigens have been found. (Control group consisted of 500 healthy persons from the same region.) A subgroup of 46 patients was examined in order to determine a frequency of 10 HLA-DR antigens. (Control group consisted of 146 persons.) A positive association was proved between sarcoidosis and the HLA-B8 and B13 antigens (RR = 2.8 and RR = 3.1, respectively). A frequency of B8B13 heterozygotes was highly significant (RR = 8.5). The observed antigen genotype frequencies may be explained by the hypothesis of 2 HLA-linked disposing genes.

Biomarkers↗